A Dutch study has focused on an intestinal bacterium called Akkermansia muciniphila. Participants who took it as a supplement after a diet regained only 13.6% of the lost weight, compared to 32.9% in the placebo group. Their insulin sensitivity also improved. It seems like a serious advance against the dreaded rebound effect, but beware of what comes next.
Modest science, runaway marketing 🧪
The study, published in Nature Medicine, is small: 90 people. The bacterium is not marketed as a supplement, but companies are already warming up their engines. The pattern is well-known: modest findings turn into promises of a magic pill. It happened with probiotics, prebiotics, and ferments. The problem is not the data, but how it is interpreted in wellness headlines. The average person cannot distinguish a paper from an advertorial, and will end up buying expensive capsules with hope, not certainty.
The pill doesn't exist, but the margin does 💰
The real solution remains boring: real diet, exercise, and time. That is not sold in pharmacies, has no margin, and cannot be patented. In contrast, a bacterium with a scientific name sounds like a revolution. Laboratories know it: it's better to sell bugs with a pretty label than to explain that losing weight requires sweating and not eating pizza for dinner. Meanwhile, those who want to take care of themselves should keep reading. And not swallow anything without asking first.